Vascular Endothelial Growth Factor Expression in Canine Intracranial Meningiomas and Association with Patient Survival

Platt, Simon; Scase, T.; Adams, Vicki; Wieczorek, Lara; Miller, J W; Adamo, Filippo; Long, Sam

doi:10.1892/0891-6640(2006)20[663:vegfei]2.0.co;2

Cited by 31 publications

(38 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Veterinary trials with toceranib and masitinib have shown benefit in several cancers but have not been reported for brain tumors. Documented overexpression of VEGF, VEGF receptors, and PDGFR alpha in some canine brain tumors108, 109, 110, 111, 112, 113, 114, 115, 116 may justify trials with these or similar small molecules in defined patients.…”

Section: Novel Therapiesmentioning

confidence: 99%

Advances in Diagnostic and Treatment Modalities for Intracranial Tumors

Dickinson

2014

Veterinary Internal Medicne

View full text Add to dashboard Cite

Intracranial neoplasia is a common clinical condition in domestic companion animals, particularly in dogs. Application of advances in standard diagnostic and therapeutic modalities together with a broad interest in the development of novel translational therapeutic strategies in dogs has resulted in clinically relevant improvements in outcome for many canine patients. This review highlights the status of current diagnostic and therapeutic approaches to intracranial neoplasia and areas of novel treatment currently in development.

show abstract

Section: Novel Therapiesmentioning

confidence: 99%

Advances in Diagnostic and Treatment Modalities for Intracranial Tumors

Dickinson

2014

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…13 With both antiangiogenic as well as antitumor effects, toceranib has potential therapeutic activity in a wide range of tumor types in dogs. [14][15][16][17][18][19][20][21][22][23] A phase I clinical trial and retrospective case series suggest that toceranib exhibits potential clinical antitumor activity against mixed mammary carcinoma, soft tissue sarcoma, multiple myeloma, AGASACA, osteosarcoma, thyroid carcinoma, head and neck carcinoma, and nasal carcinoma. 12,24 Use of toceranib for treatment of AGASACA has been evaluated in a limited number of studies.…”

mentioning

confidence: 99%

Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs

Heaton

Fernandes

Jark

et al. 2020

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background There is no widely accepted standard medical treatment for apocrine gland anal sac adenocarcinoma (AGASACA) in dogs. Targeted agents such as toceranib may be effective in treatment of AGASACA, but the number of clinical reports investigating its efficacy is limited. Hypothesis/Aim To evaluate the efficacy of toceranib treatment of AGASACA in dogs, and to assess prognostic factors in the study population. Our hypothesis was that toceranib would provide a clinical benefit in the treatment of dogs with AGASACA. Animals Thirty‐six client‐owned dogs with either a cytologic or histologic diagnosis of AGASACA that were treated with toceranib alone or in combination with surgery, nonconcurrent chemotherapy or both. Methods Retrospective study. Result The median progression‐free survival (PFS) and overall survival time (OST) for the study population was 313 days and 827 days, respectively. A clinical benefit from toceranib treatment was observed in 69% of dogs, with 20.7% of dogs experiencing partial response and 48.3% of dogs experiencing stable disease. Dogs that responded to toceranib treatment had significantly prolonged PFS and OST. Hypercalcemia was a negative prognostic factor for clinical outcomes. Conclusions Toceranib is effective in the treatment of AGASACA in dogs. Prospective, controlled clinical trials are needed to determine the efficacy of toceranib in comparison to other treatment protocols for dogs with AGASACA.

show abstract

“…73 Canine meningiomas also express high levels of VEGF and preliminary work confirms an association with outcome following surgical resection and radiotherapy. 74 The level of VEGF expression may indicate the degree of malignancy in canine meningiomas, but it does not seem to be associated with cyclooxygenase-2 expression, which is an independent indicator of malignancy in human meningiomas. The growth of meningiomas seems less dependent on the up-regulation of VEGF by hypoxia and tumour necrosis and may be corticosteroid dependent, with some evidence indicating that VEGF expression may be related to stimulation of the oestrogen/progesterone system.…”

Section: Meningiomasmentioning

confidence: 94%

“…Recent work has highlighted increased levels of VEGF expressed in canine meningiomas and has demonstrated an association with patient survival. 74 However, ongoing work at the author's institution includes investigating the association of VEGF expression and PTO in canine meningiomas and treatment trials using locally delivered cell-encapsulated anti-angiogenic therapy in dogs with cerebral neoplasia.…”

Section: Angiogenesis and The Veterinary Experiencementioning

confidence: 99%

Angiogenesis and cerebral neoplasia

Platt

2005

Vet Comparative Oncology

View full text Add to dashboard Cite

Angiogenesis is a fundamental process in reproduction and wound healing. It is a tightly regulated process causing neovascularization. However, if angiogenesis becomes unregulated, it may be responsible for several disease processes such as brain tumour growth and metastasis. An understanding of the factors implicated in angiogenesis and its inhibition is essential if they are to be exploited as possible clinical treatments for brain tumours. Unfortunately, there are multiple factors known to be involved in the regulation of angiogenesis, and hence, the clinical application of any single agent may not be effective. This article summarizes the processes of blood vessel formation in the brain, examines the angiogenic factors that are important in the nervous system and discusses their role in brain tumour development and possible treatment.

show abstract

Vascular Endothelial Growth Factor Expression in Canine Intracranial Meningiomas and Association with Patient Survival

Abstract: The extent of VEGF expression in canine intracranial meningiomas may be used as a prognostic marker and suggests a potential future target for therapy.

Cited by 31 publications

References 27 publications

Advances in Diagnostic and Treatment Modalities for Intracranial Tumors

Advances in Diagnostic and Treatment Modalities for Intracranial Tumors

Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs

Angiogenesis and cerebral neoplasia

Contact Info

Product

Resources

About